e-ISSN 2598-3849       print ISSN 2527-8878

Vol 3, No 1 (2018)

ECONOMIC EVALUATION OF CETUXIMAB FOR METASTATIC COLORECTAL CANCER (mCRC): A PROTOCOL FOR EVIDENCE SYNTHESIS

Septiara Putri, Ery Setiawan, Siti Rizny F Saldi, Levina Chandra, Amila Megraini, Vetty Yulianty P

Abstract


 

ABSTRACT

Colorectal cancer is fairly common compared to other cancers. The incidence and mortality rates are predicted to increase globally. In some cases, cancer can be potentially spread to another organ or metastatic. One of recent available targeted therapies for metastatic colorectal cancer (mCRC) patient is Cetuximab (Erbitux ®), combined with chemotherapy. Despite clinical effectiveness, there is the importance of the evidence related cost-effectiveness of therapy. This study aims to summary, synthesize, and systematically review the economic evaluation studies of Cetuximab for metastatic colorectal cancer (mCRC). Model based economic evaluation of Cetuximab for metastatic colorectal cancer will be searched and included in the review based on specific eligibility criteria. Several electronic databases that will be used: Medline, Embase, Cochrane, National Institute of Health Research (NIHR) Center for Reviews and Dissemination. Full economic evaluation evidence will be summarized and critically appraised using Drummond as well as (Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. In terms of analysis, we will qualitatively appraise and present the studies that meet our inclusion and exclusion criteria. We are expected to summarize the quality and capture the valuable insights related to health economic evaluation studies of Cetuximab for mCRC patient.

 

ABSTRAK

Kanker kolorektal cukup umum terjadi dibandingkan kanker lainnya, angka kejadian dan angka kematian diprediksi meningkat secara global. Dalam beberapa kasus, kanker berpotensi menyebar ke organ lain atau disebut metastasis. Salah satu terapi yang ditargetkan baru-baru ini untuk pasien kanker kolorektal metastatik (mCRC) adalah Cetuximab (Erbitux®), yang dikombinasikan dengan kemoterapi. Meskipun terdapat bukti klinis, penting untuk mempertimbangkan bukti terkait efektivitas biaya dari terapi tersebut. Penelitian ini bertujuan untuk merangkum, mensintesis, dan meninjau secara sistematis studi evaluasi ekonomi Cetuximab untuk kanker kolorektal metastatik (mCRC). Evaluasi ekonomi berbasis model untuk menilai Cetuximab pada kanker kolorektal metastatik akan ditelusuri sesuai dengan kriteria yang ditetapkan. Beberapa database elektronik yang akan digunakan: Medline, Embase, Cochrane, Pusat Penelitian Kesehatan Nasional (NIHR) untuk Tinjauan dan Diseminasi. Bukti evaluasi ekonomi lengkap akan dirangkum dan dinilai secara kritis dengan menggunakan daftar pertanyaan oleh Drummond dan juga Consolidated Health Economic Evaluation Reporting Standards (CHEERS). Dalam hal analisis, kami akan menilai dan menyajikan secara kualitatif studi yang memenuhi kriteria inklusi dan eksklusi. Kami berekspektasi untuk meyimpulkan kualitas dan menangkap informasi yang berkaitan dengan studi evaluasi ekonomi pada Cetuximab untuk pasien mCRC.


Keywords


economic evaluation; cetuximab; erbitux; colorectal cancer

References


(1) Arnold, M., Sierra, M.S., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F., 2016. Global patterns and trends in colorectal cancer incidence and mortality. Gut, pp.gutjnl-2015.

(2) Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J.T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C. and Loos, A.H., 2008. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. Journal of clinical oncology, 27(5), pp.663-671.

(3) Drummond, M.F., Sculpher, M.J., Claxton, K., Stoddart, G.L. and Torrance, G.W., 2015. Methods for the economic evaluation of health care programmes. Oxford university press.

(4) Chan, D.L.H., Segelov, E., Wong, R.S., Smith, A., Herbertson, R.A., Li, B.T., Tebbutt, N., Price, T. and Pavlakis, N., 2017. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. The Cochrane Library.

(5) Ewara, Emmanuel M.G., "The Cost-Effectiveness of Combination Treatment Consisting of Either Cetuximab or Panitumumab plus FOLFIRI versus Treatment with Bevacizumab plus FOLFIRI as First-Line Treatment for KRAS Wild-Type Metastatic Colorectal Cancer Patients in Ontario" (2012). Electronic Thesis and Dissertation Repository. 927.

(6) Favoriti, P., Carbone, G., Greco, M., Pirozzi, F., Pirozzi, R.E.M. and Corcione, F., 2016. Worldwide burden of colorectal cancer: a review. Updates in surgery, 68(1), pp.7-11.

(7) Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D. and Bray, F., 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer, 136(5).

(8) Field, K. and Lipton, L., 2007. Metastatic colorectal cancer-past, progress and future. World journal of gastroenterology: WJG, 13(28), p.3806.

(9) Gao, G., Zhou, X., Huang, R., Jiang, J., Chu, Z. and Liang, X., 2009. Cetuximab for the treatment of metastatic colorectal cancer: a meta-analysis. Tumor, 29(3), pp.253-258.

(10) Gerber, D.E., 2008. Targeted therapies: a new generation of cancer treatments. American family physician, 77(3).

(11) Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A.H., Mauskopf, J. and Loder, E., 2013. Consolidated health economic evaluation reporting standards (CHEERS) statement. Cost Effectiveness and Resource Allocation, 11(1), p.6.

(12) Jansman, F.G., Postma, M.J. and Brouwers, J.R., 2007. Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics, 25(7), pp.537-562.

(13) Lange, A., Prenzler, A., Frank, M., Kirstein, M., Vogel, A. and Von Der Schulenburg, J.M., 2014. A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. European journal of cancer, 50(1), pp.40-49.

(14) Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V. and Ducreux, M., 2009. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. Journal of clinical oncology, 27(35), pp.5924-5930.

(15) Martinelli, E., De Palma, R., Orditura, M., De Vita, F. and Ciardiello, F., 2009. Anti‐epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clinical & Experimental Immunology, 158(1), pp.1-9.

(16) Mittmann, N., Au, H.J., Tu, D., O'callaghan, C.J., Isogai, P.K., Karapetis, C.S., Zalcberg, J.R., Evans, W.K., Moore, M.J., Siddiqui, J. and Findlay, B., 2009. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO. 17 trial. Journal of the National Cancer Institute, 101(17), pp.1182-1192.

(17) Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G. and Prisma Group, 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine, 6(7), p.e1000097.

(18) The National Cancer Comprehensive Cancer Network (NCCN) Guidelines for Patients. Colon Cancer, version 1.2017. Accessed: 02 January 2017. URL: https://www.nccn.org/patients/guidelines/colon/files/assets/common/downloads/files/colon.pdf

(19) Reynolds, N.A. and Wagstaff, A.J., 2004. Cetuximab. Drugs, 64(1), pp.109-118.

(20) Rinaldi, F., George, E. and Adler, A.I., 2012. NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy.

(21) Silva, W.C., Abreu Lima, E.M., Araújo, V.E., Santos, J.B.R., Silva, M.R.R., Acúrcio, F.A., Cherchiglia, M.L. and Andrade, E.I.G., 2017. Comparative effectiveness and safety of monoclonal antibodies (bevacizumab, cetuximab and panitumumab) in the treatment of metastatic colorectal cancer: Systematic review and metanalysis.

(22) Systematic Reviews. CRD’s Guidance for Undertaking Reviews in Healthcare. Centre for Reviews and Dissemination, University of York, 2008 Accessed: 02 January 2017 URL: https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf

(23) Tappenden, P., Jones, R., Paisley, S. and Carroll, C., 2007. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

(24) Van der Geest, L.G., Koopman, M., Verhoef, C., Elferink, M.A. and de Wilt, J.H., 2015. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clinical & experimental metastasis, 32(5), pp.457-465.

(25) Van Cutsem, E., Köhne, C.H., Láng, I., Folprecht, G., Nowacki, M.P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S. and Schlichting, M., 2011. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Journal of Clinical Oncology, 29(15), pp.2011-2019.

(26) Yang, Y.F., Wang, G.Y., He, J.L., Wu, F.P. and Zhang, Y.N., 2017. Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer: A meta-analysis. Medicine, 96(12).

(27) Yarom, N. and Jonker, D.J., 2011. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Discovery medicine, 11(57), pp.95-105.


Full Text: PDF

DOI: 10.7454/eki.v3i1.2304

Refbacks

  • There are currently no refbacks.